These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 11078803

  • 1. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
    Cataldo L, Chen NY, Yuan Q, Li W, Ramamoorthy P, Wagner TE, Sticca RP, Chen WY.
    Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
    [Abstract] [Full Text] [Related]

  • 2. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
    Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V.
    Oncogene; 2000 Sep 28; 19(41):4695-705. PubMed ID: 11032019
    [Abstract] [Full Text] [Related]

  • 3. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT, Chen NY, Franek KJ, Chen WY.
    Cancer Res; 2003 Jul 01; 63(13):3598-604. PubMed ID: 12839947
    [Abstract] [Full Text] [Related]

  • 4. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
    Langenheim JF, Chen WY.
    Breast Cancer Res Treat; 2005 Apr 01; 90(3):281-93. PubMed ID: 15830142
    [Abstract] [Full Text] [Related]

  • 5. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G, Li W, Holle L, Chen N, Chen WY.
    Clin Cancer Res; 2002 Apr 01; 8(4):1196-205. PubMed ID: 11948133
    [Abstract] [Full Text] [Related]

  • 6. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.
    Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE.
    Clin Cancer Res; 1999 Nov 01; 5(11):3583-93. PubMed ID: 10589775
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells.
    Ramamoorthy P, Sticca R, Wagner TE, Chen WY.
    Int J Oncol; 2001 Jan 01; 18(1):25-32. PubMed ID: 11115535
    [Abstract] [Full Text] [Related]

  • 9. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.
    Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY.
    Int J Oncol; 2002 Apr 01; 20(4):813-8. PubMed ID: 11894130
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY.
    Breast Cancer Res Treat; 2008 Sep 01; 111(2):241-50. PubMed ID: 17955362
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
    Friedrichsen BN, Galsgaard ED, Nielsen JH, Møldrup A.
    Mol Endocrinol; 2001 Jan 01; 15(1):136-48. PubMed ID: 11145745
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone.
    Shiu RP, Paterson JA.
    Cancer Res; 1984 Mar 01; 44(3):1178-86. PubMed ID: 6692402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.